Cargando…

Riociguat in Patients with CTEPH and Advanced Age and/or Comorbidities

Riociguat is licensed for the therapy of inoperable chronic thromboembolic pulmonary hypertension (CTEPH). We aimed to investigate whether age and comorbidities influence its tolerability and efficacy. Retrospectively, we analyzed data of tolerability, non-invasive, and invasive efficacy at baseline...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barnikel, Michaela, Kneidinger, Nikolaus, Arnold, Paola, Waelde, Andrea, Behr, Jürgen, Milger, Katrin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877433/ https://www.ncbi.nlm.nih.gov/pubmed/35207354 http://dx.doi.org/10.3390/jcm11041084

Ejemplares similares

Real‐life effectiveness of biological therapies on symptoms in severe asthma with comorbid CRSwNP
por: Mümmler, Carlo, et al.
Publicado: (2021)

Domestic Parasitic Infections in Patients with Asthma and Eosinophilia in Germany – Three Cases with Learnings in the Era of Anti- IL5 Treatments
por: Barnikel, Michaela, et al.
Publicado: (2023)

Clinical Impact of Physical Activity and Cough on Disease Progression in Fibrotic Interstitial Lung Disease
por: Veit, Tobias, et al.
Publicado: (2023)

Real-World Switching to Riociguat: Management and Practicalities in Patients with PAH and CTEPH
por: Gall, Henning, et al.
Publicado: (2018)

Switching to riociguat: a potential treatment strategy for the management of CTEPH and PAH
por: Benza, Raymond L., et al.
Publicado: (2020)

Haemodynamic effects of riociguat in CTEPH and PAH: a 10-year observational study
por: Yang, Suqiao, et al.
Publicado: (2021)

Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences
por: Andersen, Asger, et al.
Publicado: (2017)

Differential response to biologics in a patient with severe asthma and ABPA: a role for dupilumab?
por: Mümmler, Carlo, et al.
Publicado: (2020)

Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension (CTEPH) or pulmonary arterial hypertension (PAH)
por: Ghofrani, Hossein A, et al.
Publicado: (2009)

Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study
por: Veit, Tobias, et al.
Publicado: (2020)

Identification of a novel SERPINA-1 mutation causing alpha-1 antitrypsin deficiency in a patient with severe bronchiectasis and pulmonary embolism
por: Milger, Katrin, et al.
Publicado: (2015)

Beneficial effects of riociguat on hemodynamic responses to exercise in CTEPH patients after balloon pulmonary angioplasty – A randomized controlled study
por: Aoki, Tatsuo, et al.
Publicado: (2020)

Pulmonary function impairment of asymptomatic and persistently symptomatic patients 4 months after COVID-19 according to disease severity
por: Munker, Dieter, et al.
Publicado: (2021)

Daily Chronic Intermittent Hypobaric Hypoxia Does Not Induce Chronic Increase in Pulmonary Arterial Pressure Assessed by Echocardiography
por: Götschke, Jeremias, et al.
Publicado: (2018)

Efficacy of pre-exposure prophylaxis to prevent SARS-CoV-2 infection after lung transplantation: a two center cohort study during the omicron era
por: Gottlieb, Jens, et al.
Publicado: (2023)

Real-World Multicenter Experience with Mepolizumab and Benralizumab in the Treatment of Uncontrolled Severe Eosinophilic Asthma Over 12 Months
por: Kayser, Moritz Z, et al.
Publicado: (2021)

Response to high-altitude triggers in seasonal asthmatics on and off inhaled corticosteroid treatment
por: Mertsch, Pontus, et al.
Publicado: (2022)

Perception of climate change in patients with chronic lung disease
por: Götschke, Jeremias, et al.
Publicado: (2017)

Dynamics of SARS-CoV-2 shedding in the respiratory tract depends on the severity of disease in COVID-19 patients
por: Munker, Dieter, et al.
Publicado: (2021)

NOVEL CTEPH MIMICKERS IN THE COVID-19 ERA
por: Pietrowicz, Rylie, et al.
Publicado: (2022)

Effects of riociguat in severe experimental pulmonary hypertension
por: Kojonazarov, Baktybek, et al.
Publicado: (2011)

Incidence, causes, and predictors of unsuccessful decannulation following prolonged weaning
por: Ghiani, Alessandro, et al.
Publicado: (2022)

Effects of age and gender on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat
por: Frey, Reiner, et al.
Publicado: (2013)

Riociguat: PATENT-1 Study
por: Said, Karim
Publicado: (2014)

Central versus Peripheral CTEPH—Clinical and Hemodynamic Specifications
por: Kaldararova, Monika, et al.
Publicado: (2022)

Impact of ILD-Specific Therapies on Perioperative Course in Patients with Progressive Interstitial Lung Disease Undergoing Lung Transplantation
por: Munker, Dieter, et al.
Publicado: (2023)

High prevalence of falsely declaring nicotine abstinence in lung transplant candidates
por: Veit, Tobias, et al.
Publicado: (2020)

Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH)
por: Escribano-Subias, Pilar, et al.
Publicado: (2019)

Epidemiology of chronic thromboembolic pulmonary hypertension (CTEPH) in the Czech Republic
por: Jansa, Pavel, et al.
Publicado: (2022)

Clinical Pharmacokinetic and Pharmacodynamic Profile of Riociguat
por: Frey, Reiner, et al.
Publicado: (2017)

Impact of Lung Function Decline on Mortality in Lung Transplant Recipients: Long-Term Results From the L-CsA-i Study for the Prevention of Bronchiolitis Obliterans Syndrome
por: Kneidinger, Nikolaus, et al.
Publicado: (2022)

Practical management of riociguat in patients with pulmonary arterial hypertension
por: Halank, Michael, et al.
Publicado: (2019)

Cardiopulmonary exercise testing and pulmonary function testing for predicting the severity of CTEPH
por: Zhu, Hanqing, et al.
Publicado: (2021)

Pulmonary artery sarcoma presenting as chronic thromboembolic pulmonary hypertension (CTEPH)
por: Ampatzidou, Fotini, et al.
Publicado: (2023)

Pharmacokinetic interaction of ketoconazole, clarithromycin, and midazolam with riociguat
por: Becker, Corina, et al.
Publicado: (2013)

Riociguat: Something new in pulmonary hypertension therapeutics?
por: Shanmugam, Elangovan, et al.
Publicado: (2015)

Riociguat: Clinical research and evolving role in therapy
por: Klinger, James R., et al.
Publicado: (2020)

Inherited Thrombophilia in Chinese CTEPH Patients: A Rather Common Finding in an Uncommon Condition
por: Kearney, Katherine, et al.
Publicado: (2022)

Comparison of MRI and VQ-SPECT as a Screening Test for Patients With Suspected CTEPH: CHANGE-MRI Study Design and Rationale
por: Lasch, Florian, et al.
Publicado: (2020)

Local and Systemic RAGE Axis Changes in Pulmonary Hypertension: CTEPH and iPAH
por: Moser, Bernhard, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_506n8rpkst76p2jo9s5p9f1k1i